Interaction of human multidrug and toxin extrusion 1 (MATE1) transporter with antineoplastic agents

Drug Metabolism and Drug Interactions

Volumn 26, Issue 4, 2011, Pages 181-189

  Grottker, Julia ^a   Rosenberger, Albert ^a   Burckhardt, Gerhard ^a   Hagos, Yohannes ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

antineoplastic agents; MATE1; SLC transporter

Indexed keywords

CARRIER PROTEIN; IRINOTECAN; MITOXANTRONE; PROTEIN MULTIDRUG AND TOXIN EXTRUSION 1; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE; VINDESINE;

ARTICLE; CELL STRAIN HEK293; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EXCRETION; DRUG METABOLISM; HUMAN; HUMAN CELL; NONHUMAN; PROTEIN INTERACTION; TUMOR CELL;

ANTINEOPLASTIC AGENTS; CAMPTOTHECIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HEK293 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; MITOXANTRONE; ORGANIC CATION TRANSPORT PROTEINS; TRANSFECTION;

EID: 83655183203     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/DMDI.2011.024     Document Type: Article

References (32)

1. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the fi nal excretion step for toxic organic cations. Proc Natl Acad Sci USA 2005;102:17923-8. (Pubitemid 41798478)
2. Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specifi city of MATE1 and MATE2-K, human multidrug and toxin extrusions/H( + )-organic cation antiporters. Biochem Pharmacol 2007;74:359-71. (Pubitemid 46890818)
3. Ohta K, Imamura Y, Okudaira N, Atsumi R, Inoue K, Yuasa H. Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fl uoroquinolones. J Pharmacol Exp Ther 2009;328:628-34.
4. Morita Y, Kodama K, Shiota S, Mine T, Kataoka A, Mizushima T, et al. NorM, a putative multidrug effl ux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob Agents Chemother 1998;42:1778-82. (Pubitemid 28311578)
5. Brown MH, Paulsen IT, Skurray RA. The multidrug effl ux protein NorM is a prototype of a new family of transporters. Mol Microbiol 1999;42:394-5. (Pubitemid 29012178)
6. Terada T, Inui KI. Physiological and pharmacokinetic roles of H + /organic cation antiporters (MATE/SLC47A)11. Biochem Pharmacol 2008;75:1689-96.
7. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui Ki. Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1-3 and Multidrug and Toxin Extrusion Family). J Pharmacol Exp Ther 2006;319:879-86.
8. Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol 2010;298:F997-1005.
9. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identifi cation and functional characterization of a new human kidney-specifi c H + /organic cation antiporter, kidney-specifi c multidrug and toxin extrusion 2. J Am Soc Nephrol 2006;17:2127-35. (Pubitemid 44141902)
10. Shnitsar V, Eckardt R, Gupta S, Grottker J, Muller GA, Koepsell H, et al. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 2009;69:1494-501.
11. Watanabe S, Tsuda M, Terada T, Katsura T, Inui K. Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1- defi cient mice. J Pharmacol Exp Ther 2010;334:651-6.
12. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther 2011;10:531-9.
13. Chen Y, Zhang S, Sorani M, Giacomini KM. Transport of paraquat by human organic cation transporters and multidrug and toxic compound extrusion family. J Pharmacol Exp Ther 2007;322:695-700. (Pubitemid 47105798)
14. Nakamura T, Yonezawa A, Hashimoto S, Katsura T, Inui Ki. Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem Pharmacol 2010;80:1762-7.
15. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, et al. Organic Cation Transporters Are Determinants of Oxaliplatin Cytotoxicity. Cancer Res 2006;66:8847-57. (Pubitemid 44449203)
16. Sato T, Masuda S, Yonezawa A, Tanihara Y, Katsura T, Inui K. Transcellular transport of organic cations in double-transfected MDCK cells expressing human organic cation transporters hOCT1/hMATE1 and hOCT2/hMATE1. Biochem Pharmacol 2008;76:894-903.
17. Fassberg J, Stella VJ. A kinetic and mechanistic study of the hydrolysis of camptothecin and some analogues. J Pharm Sci 1992; 81:676-84. (Pubitemid 23006796)
18. Tsuda M, Terada T, Ueba M, Sato T, Masuda S, Katsura T, et al. Involvement of Human Multidrug and Toxin Extrusion 1 in the Drug Interaction between Cimetidine and Metformin in Renal Epithelial Cells. J Pharmacol Exp Ther 2009;329:185-91.
19. Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE Protein Inhibitor, Pyrimethamine, on the Renal Elimination of Metformin at Oral Microdose and at Therapeutic Dose in Healthy Subjects. Clin Pharmacol Ther 2011;89:837-44.
20. Schornack PA, Gillies RJ. Contributions of cell metabolism and H + diffusion to the acidic pH of tumors. Neoplasia 2003;5:135-45. (Pubitemid 36369009)
21. Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo effi cacy of weak acid and base chemotherapeutics. Mol Cancer Ther 2006;5:1275-9. (Pubitemid 43881320)
22. Bhujwalla ZM, Artemov D, Ballesteros P, Cerdan S, Gillies RJ, Solaiyappan M. Combined vascular and extracellular pH imaging of solid tumors. NMR Biomed 2002;15:114-9. (Pubitemid 34213401)
23. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36.
24. Aoki M, Terada T, Kajiwara M, Ogasawara K, Ikai I, Ogawa O, et al. Kidney-specifi c expression of human organic cation transporter 2 (OCT2/SLC22A2) is regulated by DNA methylation. Am J Physiol Renal Physiol 2008;295:F165-170.
25. Zolk O, Fromm MF. Transporter-Mediated Drug Uptake and Effl ux: Important Determinants of Adverse Drug Reactions. Clin Pharmacol Ther 2011;89:798-805.
26. Rizwan AN, Burckhardt G. Organic anion transporters of the SLC22 family: biopharmaceutical, physiological, and pathological roles. Pharm Res 2007;24:450-70. (Pubitemid 46295167)
27. Koenig J, Zolk O, Singer K, Hoffmann C, Fromm MF. Doubletransfected MDCK cells expressing human OCT1/MATE1 or OCT2/MATE1: determinants of uptake and transcellular translocation of organic cations. Br J Pharmacol 2001;163: 546-55.
28. Lai Y, Sampson KE, Balogh LM, Brayman TG, Cox SR, Adams WJ, et al. Preclinical and Clinical Evidence for the Collaborative Transport and Renal Secretion of an Oxazolidinone Antibiotic by Organic Anion Transporter 3 (OAT3/SLC22A8) and Multidrug and Toxin Extrusion Protein 1 (MATE1/SLC47A1). J Pharmacol Exp Ther 2010;334:936-44.
29. Filipski KK, Mathijssen RH, Mikkelsen TS, Schinkel AH, Sparreboom A. Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity. Clin Pharmacol Ther 2009;86:396-402.
30. Gupta S, Burckhardt G, Hagos Y. SLC22 transporter family proteins as targets for cytostatic uptake into tumor cells. Biol Chem 2011;392:117-24.
31. Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, et al. Characterization of the organic cation transporter SLC22A16: a doxorubicin importer. Biochem Biophys Res Commun 2005;333:754-62. (Pubitemid 40854224)
32. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, et al. Profi ling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 2008;7:3081-91.